BridgeBio Pharma LLC - Oct 10, 2025 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Role
10%+ Owner
Signature
/s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma LLC
Stock symbol
BBOT
Transactions as of
Oct 10, 2025
Transactions value $
$0
Form type
4
Date filed
10/16/2025, 05:54 PM
Previous filing
Aug 18, 2025
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
BridgeBio Pharma LLC 10%+ Owner C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DRIVE, SUITE 250, PALO ALTO /s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma LLC 2025-10-16 0002076615
BridgeBio Pharma, Inc. 10%+ Owner 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma, Inc. 2025-10-16 0001743881

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBOT Common Stock Other +785K +5.68% 14.6M Oct 10, 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025 in exchange for additional financial and accounting support services provided through December 31, 2025.
F2 Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collectively, the "BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any.
F3 (Continued from Footnote 2) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.